Literature DB >> 6498853

Sensitive radioimmunoassay for cytarabine and uracil arabinoside in plasma.

T Sato, M Morozumi, K Kodama, A Kuninaka, H Yoshino.   

Abstract

A sensitive and specific radioimmunoassay for cytarabine (ara-C) or uracil arabinoside (ara-U) was established by using [3H]ara-C and anti-ara-C antiserum or [3H]ara-U and anti-ara-U antiserum. The antiserum was prepared by immunizing rabbits with ara-C or ara-U hapten conjugated to human albumin. In the present assay, as low as 2.5 ng/ml (0.01 microM) of ara-C or 5 ng/ml (0.02 microM) of ara-U in blood plasma samples could be detected. The cross-reaction of ara-C or ara-U structurally related compounds with each antiserum was so small that the nucleosides could be determined without any purification procedure. The plasma concentration of ara-C and ara-U in mice following oral administration of an antileukemic agent, cytosine arabinoside-5'-stearylphosphate (C18PCA) (100 mg/kg), or ara-C (48 mg/kg) was determined by using this method. In the case of C18PCA administration, ara-C was detectable in blood for at least 24 hours longer than in the case of ara-C administration. This method is suitable for the analysis of ara-C and ara-U, the metabolites of depot drugs of ara-C such as C18PCA.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6498853

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  7 in total

1.  Characteristic antitumor activity of cytarabine ocfosfate against human colorectal adenocarcinoma xenografts in nude mice.

Authors:  K Koga; E Iizuka; A Sato; H Ekimoto; M Okada
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

2.  Deoxyribonucleoside triphosphate pools and Ara-CTP levels in P388 murine leukemic cells treated with 1-B-D-arabinofuranosylcytosine-5'-stearylphosphate which is a newly synthesized derivative of 1-B-D-arabinofuranosylcytosine.

Authors:  M Higashigawa; H Hori; T Ohkubo; H Kawasaki; T Yoshizumi; M Sakurai
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

3.  Combined oral administration of etoposide and arabinofuranosylcytosine-5'-stearylphosphate enhances the antitumor effect against P388 ascites tumors.

Authors:  M Higashigawa; D C Cao; K Matsui; S Yamada; H Kakitou; Y Kagawa; H Inamochi; M Ido; M Sakurai
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Sensitive and specific radioimmunoassay for fialuridine: initial assessment of pharmacokinetics after single oral doses to healthy volunteers.

Authors:  R R Bowsher; J A Compton; J A Kirkwood; G D Place; C D Jones; T E Mabry; D L Hyslop; B L Hatcher; K A DeSante
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

5.  The value of oral cytarabine ocfosfate and etoposide in the treatment of refractory and elderly AML patients.

Authors:  Akira Horikoshi; Kazuhiro Takei; Yoshifumi Hosokawa; Shigemasa Sawada
Journal:  Int J Hematol       Date:  2008-01-30       Impact factor: 2.490

6.  Antitumor activity and pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate: an orally active derivative of 1-beta-D-arabinofuranosylcytosine.

Authors:  K Kodama; M Morozumi; K Saitoh; A Kuninaka; H Yoshino; M Saneyoshi
Journal:  Jpn J Cancer Res       Date:  1989-07

7.  Validation of a Novel Potentiometric Method Based on a Polymeric PVC Membrane Sensor Integrated with Tailored Receptors for the Antileukemia Drug Cytarabine.

Authors:  Ayman H Kamel; Abd El-Galil E Amr; Nashwa H Ashmawy; Hoda R Galal; Abdulrahman A Almehizia; Teraze A Youssef; Mohamed A Al-Omar; Ahmed Y A Sayed
Journal:  Polymers (Basel)       Date:  2020-06-14       Impact factor: 4.329

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.